汇宇制药：取得药品注册证书

Group 1 - The core point of the article is that Huayu Pharmaceutical has received approval from the National Medical Products Administration for its product, Etoposide Injection, which is a significant regulatory milestone for the company [1] - As of the latest report, Huayu Pharmaceutical's revenue composition for the year 2024 is heavily weighted towards pharmaceuticals, with 99.18% of revenue coming from this sector, indicating a strong focus on its core business [2] - The current market capitalization of Huayu Pharmaceutical is 9.1 billion yuan, reflecting its position in the market [3]